Efaproxiral Sodium |
Catalog No.GC14586 |
L'éfaproxiral sodique (RSR13 sodique) est un modificateur allostérique synthétique de l'hémoglobine (Hb), diminue l'affinité de liaison Hb-oxygène (O2) et améliore l'oxygénation des tumeurs hypoxiques pendant la radiothérapie.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 170787-99-2
Sample solution is provided at 25 µL, 10mM.
Efaproxiral sodium is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy.in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT.
References:
[1]. Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94(12):1777-1784.
Average Rating: 5
(Based on Reviews and 36 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *